Merck's OAB Patch Gets FDA Nod - Analyst Blog

By
A A A

Merck ( MRK ) recently announced that it has received US Food and Drug Administration (FDA) approval for its transdermal patch, Oxytrol for Women (oxybutynin transdermal system). The drug has been approved for treating women suffering from overactive bladder (OAB). The company expects the drug to be available from fall of 2013.

The FDA approval of Oxytrol for Women marks the first approval of an over-the-counter (OTC) treatment for overactive bladder in women. Oxytrol for Women has a proven safety profile with oxybutynin, the active ingredient of the drug, being used for treating OAB for more than 30 years. 

The company licensed the exclusive commercialization rights regarding Oxytrol for Women from Watson Pharmaceuticals, Inc., which is currently known as Actavis, Inc. ( ACT ).

The drug offers significant commercial potential. Merck stated in its press release that although OAB, which affects more than 20 million women in the US, can be treated, more than 80% of women with OAB remain untreated.

We note that Merck has entered into a challenging period with erstwhile blockbuster drug, Singulair, losing exclusivity in the US in early Aug 2012. Other headwinds remain in the form of EU pricing pressure, US health care reform, unfavorable currency movement, the Remicade/Simponi transition and pipeline setbacks.

We believe the company will continue resorting to cost-cutting initiatives to drive the bottom line. Meanwhile, some of the company's recent launches are expected to start contributing significantly to the top line in the coming quarters.

Merck carries a Zacks Rank #3 (Hold). Large-cap pharma companies that currently look better-positioned include Eli Lilly ( LLY ) and Novo Nordisk ( NVO ). Both are Zacks Rank #2 (Buy) stocks.



ACTAVIS INC (ACT): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ACT , LLY , MRK , NVO

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

100%
100%
100%
0%

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,289
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com